Opendata, web and dolomites

MEISi SIGNED

Druggable Small Molecule Inhibitor of MEIS Proteins

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEISi project word cloud

Explore the words cloud of the MEISi project. It provides you a very rough idea of what is the project "MEISi" about.

substance    efforts    motivates    pending    44    competitive    cell    biology    benefit    deaths    prestigious    customers    countries    risk    validated    journals    ncds    market    29    pbx    cardiovascular    indicate    family    protein    oncology    feasibility    drug    regulations    usd    plays    entry    pharmaceutically    strategies    significance    first    cvds    modulate    meisi    mechanisms    segment    active    company    never    startup    benchmarking    markets    meis    tools    share    national    deep    2018    proper    patented    published    commercialization    innovative    stem    massive    ending    cancer    co    10m    hoxa9    class    metabolism    3b    small    tackling    plan    diseases    globally    channels    tech    owing    therapeutics    nearly    noncommunicable    strategy    druggable    meinox    pct    diabetes    molecule    selective    tgif2    deadliest    71    molecular    inhibits    discovery    performing    global    conduct    critical    proteins    ingredients    sizes    inhibitors    accounting    nature   

Project "MEISi" data sheet

The following table provides information about the project.

Coordinator
MEINOX ILAC TEKNOLOJILERI AS 

Organization address
address: RESITPASA MAH. KATAR CAD. TEKNOKENT ARI 1 NO: 2/5 ICKAPI NO: 19
city: SARIYER ISTANBUL
postcode: 34467
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEINOX ILAC TEKNOLOJILERI AS TR (SARIYER ISTANBUL) coordinator 50˙000.00

Map

 Project objective

MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries). Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally. Never ending efforts and global targets in tackling these diseases show the importance of the development of more effective therapeutics.

MEISi is a druggable target-based small molecule, developed and validated by Meinox. MEISi inhibits the activity of MEIS protein which plays a critical role in cell metabolism and associated with NCDs. The benefit it presents to the targeted drug discovery market is to provide tools to modulate molecular mechanisms of the NCDs. The massive sizes of oncology and cardiovascular drug markets (USD $ 29.3B globally) indicate the significance of the small molecule drug discovery market which motivates Meinox to target €10M market share in 3 years after commercialization.

Meinox is a deep-tech startup established in 2018 with the main focus on novel and high-level pharmaceutically active ingredients. The company aims to research, develop, produce and market first-in-class, selective drug-like small molecule inhibitors of MEIS, PBX and TGIF2 proteins and their co-factor HOXA9.

Meinox aims to conduct a feasibility study with a risk analysis based on different market regulations. In order to improve the commercialization plan, potential customers of MEISi will be identified and strategies will be developed for each segment by defining proper channels for the MEISi product family. Market entry strategy will be validated by performing market analysis and competitive benchmarking in the target markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEISI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEISI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More